Breast Cancer Gene (BRCA) Mutations Treatment Market Outlook Highlights The Next Major Growth Opportunities
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Breast Cancer Gene (BRCA) Mutations Treatment Market Size And Revenue Forecast Through 2030
The market for treatments targeting breast cancer gene (BRCA) mutations has experienced robust expansion in recent years. Projected to rise from $5.01 billion in 2025 to $5.37 billion in 2026, this growth reflects a compound annual growth rate (CAGR) of 7.2%. Several factors drove progress during the historical period, including limited public understanding of BRCA mutations, constrained availability of genetic testing services, a continued dependence on traditional chemotherapy, a rising prevalence of breast and ovarian cancers, and the slow but steady uptake of targeted therapeutic approaches.
The market for treatments targeting BRCA gene mutations is projected to experience robust expansion over the coming years, reaching a valuation of $7 billion by 2030 with a compound annual growth rate (CAGR) of 6.9%. This anticipated growth during the forecast period is driven by progress in genomic sequencing technologies, the broadening of PARP inhibitor applications, heightened investment in precision oncology, a greater emphasis on combination therapies, and favorable reimbursement policies for genetic testing and targeted treatments. Key trends shaping this period include the increased uptake of genetic testing and early BRCA mutation screening, the widespread use of PARP inhibitors in targeted therapy, a stronger focus on preventive and risk-reduction treatment approaches, the advancement of personalized and precision oncology methods, and enhanced availability of multimodal treatment options for BRCA-related cancers.
Download A Free Sample Report For Comprehensive Market Insights:
Breast Cancer Gene (BRCA) Mutations Treatment Market Development Factors: Which Trends Are Supporting Demand?
The rising need for targeted therapies is anticipated to drive expansion in the breast cancer gene (BRCA) mutation treatment market moving forward. These therapies are medical approaches designed to precisely attack cancer cells by concentrating on genetic mutations or proteins involved in tumor growth. This growing demand stems largely from their capacity to specifically target disease-causing cells or molecules while sparing healthy tissues, leading to enhanced treatment efficacy and reduced side effects compared to conventional options. Targeted therapies aid in managing BRCA mutations by delivering precision medicines that directly address the genetic abnormalities fueling the disease, thereby improving outcomes and limiting unnecessary adverse effects. For example, in July 2023, a report from the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, indicated that at the close of Q1 2023, there were 247 gene therapies in Phase II, which increased by 5% to 260 by the end of Q2 2023. Consequently, the escalating demand for targeted therapies is fueling growth in the breast cancer gene (BRCA) mutation treatment market.
The increasing emphasis on personalised medicine is expected to boost the breast cancer gene (BRCA) mutation treatment market going forward. Personalised medicine involves customizing medical care to an individual’s distinct genetic, biological, and clinical profile. This trend is gaining momentum due to advancements in genetic testing, enabling treatments to be more accurately tailored to each person’s biological characteristics. A heightened focus on personalised medicine is reshaping the management of BRCA gene mutations by facilitating customized risk evaluation, targeted therapies like PARP inhibitors, and individualized prevention plans that maximize treatment effectiveness while reducing adverse effects, ultimately enhancing outcomes for patients with hereditary breast and ovarian cancers. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalised treatments for rare disease patients, a rise from 6 in 2022. These newly approved treatments for 2023 also included seven cancer drugs and three for other diseases and conditions. Thus, the growing emphasis on personalised medicine is driving expansion in the breast cancer gene (BRCA) mutation treatment market.
Breast Cancer Gene (BRCA) Mutations Treatment Market Segment Breakdown: Which Categories Generate The Most Revenue?
The breast cancer gene (brca) mutations treatment market covered in this report is segmented –
1) By Treatment Type: Targeted Therapies, Chemotherapy, Hormonal Therapy, Immunotherapy
2) By Indication: Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer
3) By Administration Route: Oral, Intravenous, Subcutaneous
4) By End-User: Hospitals, Clinics, Cancer Specialty Clinics
Subsegments:
1) By Targeted Therapies: Poly (ADP-Ribose) Polymerase Inhibitors, Mammalian Target Of Rapamycin Inhibitors, Cyclin-Dependent Kinase 4 And 6 Inhibitors, Tyrosine Kinase Inhibitors
2) By Chemotherapy: Platinum-Based chemotherapy, Anthracyclines, Taxanes, Antimetabolites
3) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs), Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
4) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Monoclonal Antibodies
Breast Cancer Gene (BRCA) Mutations Treatment Market Key Players And Strategic Industry Positioning
Major companies operating in the breast cancer gene (brca) mutations treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Thermo Fisher Scientific Inc., AstraZeneca PLC, Novartis AG, GSK plc, Janssen Biotech Inc., Astellas Pharma Inc., Genentech Inc., Clovis Oncology Inc., Owkin Inc., Allarity Therapeutics Inc., VBL Therapeutics
Access The Complete Breast Cancer Gene (BRCA) Mutations Treatment Market Report:
Breast Cancer Gene (BRCA) Mutations Treatment Market Largest Region By Revenue And Market Share
North America was the largest region in the breast cancer gene (BRCA) mutations treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer gene (brca) mutations treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
